Correction to: “Testosterone Treatment and Sexual Function in Men: Secondary Analysis of the T4DM (Testosterone for Diabetes) Trial” - Scorecard - MDSpire
Advertisement
Correction to: “Testosterone Treatment and Sexual Function in Men: Secondary Analysis of the T4DM (Testosterone for Diabetes) Trial”
Clinical Scorecard: Impact of Testosterone Therapy on Male Sexual Function: A Secondary Analysis from the T4DM (Testosterone for Diabetes) Study - Erratum
At a Glance
Category
Detail
Condition
Male sexual function in men with or at risk of diabetes
Key Mechanisms
Testosterone therapy effects on sexual function domains measured by IIEF-15
Target Population
Men randomized in the T4DM study (Testosterone for Diabetes)
Care Setting
Clinical trial setting involving testosterone treatment versus placebo
Key Highlights
Correction of participant data from 931 to 932 with at least one IIEF-15 domain measured.
74% of participants had complete sexual function data across study timepoints.
Baseline characteristics were well matched between testosterone and placebo groups, including PDE5 inhibitor use.
Guideline-Based Recommendations
Diagnosis
Use of IIEF-15 domains to assess male sexual function in clinical trials.
Management
Randomization to testosterone therapy or placebo for evaluation of sexual function outcomes.
Monitoring & Follow-up
Regular measurement of sexual function domains over multiple study timepoints.
Risks
No specific risks detailed in the erratum; original article should be consulted for safety data.
Patient & Prescribing Data
Men enrolled in the T4DM study, randomized to testosterone or placebo.
Baseline characteristics including PDE5 inhibitor use were balanced between groups; data completeness was 74%.
Clinical Best Practices
Ensure accurate data reporting and participant counts in clinical trial analyses.
Use validated sexual function questionnaires like IIEF-15 for outcome assessment.
Maintain balanced baseline characteristics between treatment arms to reduce bias.
